Medtronic PLC $MDT Stock Holdings Boosted by Diversify Advisory Services LLC

Diversify Advisory Services LLC raised its stake in shares of Medtronic PLC (NYSE:MDT) by 12.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 109,132 shares of the medical technology company’s stock after buying an additional 11,842 shares during the quarter. Diversify Advisory Services LLC’s holdings in Medtronic were worth $10,417,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Petredis Investment Advisors LLC increased its stake in Medtronic by 0.4% in the third quarter. Petredis Investment Advisors LLC now owns 26,369 shares of the medical technology company’s stock valued at $2,275,000 after purchasing an additional 114 shares in the last quarter. Randall & Associates Wealth Management raised its holdings in Medtronic by 9.5% in the third quarter. Randall & Associates Wealth Management now owns 3,658 shares of the medical technology company’s stock worth $316,000 after purchasing an additional 316 shares during the period. 55 North Private Wealth LLC acquired a new stake in Medtronic in the third quarter worth $208,000. Cypress Capital LLC boosted its position in shares of Medtronic by 3.1% during the third quarter. Cypress Capital LLC now owns 30,258 shares of the medical technology company’s stock worth $2,611,000 after purchasing an additional 921 shares in the last quarter. Finally, Norway Savings Bank boosted its position in shares of Medtronic by 19.2% during the third quarter. Norway Savings Bank now owns 8,185 shares of the medical technology company’s stock worth $706,000 after purchasing an additional 1,316 shares in the last quarter. 82.06% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Truist Financial reissued a “hold” rating and issued a $99.00 price target (up from $86.00) on shares of Medtronic in a report on Wednesday, September 2nd. Needham & Company LLC reaffirmed a “buy” rating on shares of Medtronic in a research note on Thursday, September 17th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $118.00 price objective on shares of Medtronic in a research note on Wednesday, September 2nd. Evercore set a $105.00 price target on Medtronic in a report on Monday, July 6th. Finally, Stifel Nicolaus increased their price target on Medtronic from $80.00 to $95.00 and gave the stock a “hold” rating in a report on Wednesday, September 2nd. Eighteen investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Medtronic has a consensus rating of “Moderate Buy” and an average target price of $102.88.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic received the CE mark for its five-device Vitalis pacemaker portfolio. The devices use conduction system pacing to stimulate the heart’s natural electrical pathways, giving Medtronic a potential product and competitive-positioning opportunity in European markets. Medtronic’s next-gen pacemaker portfolio secures CE mark
• Positive Sentiment: The company appointed Michael Marinaro as president with an expanded role and completed the MiniMed spinoff. The changes could sharpen Medtronic’s strategic focus and allow management to concentrate more closely on its core medical-device businesses. Medtronic appoints new president and completes MiniMed spinoff
• Neutral Sentiment: Industry research projects continued growth in U.S. wireless cardiac monitoring, supported by reimbursement expansion, telehealth adoption and AI-enabled wearables. The trend is favorable for Medtronic’s cardiac portfolio, but the report does not announce new company-specific revenue or contracts. U.S. Wireless Cardiac Monitoring Systems Market Size, Share, and Forecast
• Neutral Sentiment: Recent trading commentary noted that MDT had underperformed during the prior session despite broader market gains. This reflects short-term market positioning rather than a new fundamental development. Medtronic Stock Dips While Market Gains: Key Facts
• Negative Sentiment: Medtronic insiders disclosed sizable stock sales, including an executive’s preplanned sale of 10,420 shares valued at roughly $1 million and a CEO sale reported at approximately $4.75 million. Because the transactions were planned, they may not signal deteriorating business prospects, but their size can weigh on sentiment. Medtronic Insider Sold Shares Worth $1,000,320
• Negative Sentiment: ETFs recorded approximately $94.9 million in net selling of MDT on October 16, indicating some passive or quantitative-fund pressure, though the impact may be temporary. Medtronic Sees $94.9 Million in Net ETF Selling

Medtronic Stock Up 1.9%

Shares of MDT stock opened at $94.56 on Wednesday. The firm has a fifty day moving average of $91.18 and a 200-day moving average of $85.11. The company has a quick ratio of 1.54, a current ratio of 2.07 and a debt-to-equity ratio of 0.50. Medtronic PLC has a 12-month low of $73.31 and a 12-month high of $106.33. The company has a market capitalization of $120.96 billion, a price-to-earnings ratio of 16.22, a P/E/G ratio of 2.17 and a beta of 0.55.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, beating the consensus estimate of $1.39 by $0.06. The business had revenue of $9.76 billion for the quarter, compared to analysts’ expectations of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The firm’s revenue was up 13.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. As a group, equities research analysts predict that Medtronic PLC will post 5.98 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, October 16th. Shareholders of record on Friday, September 25th were paid a $0.72 dividend. The ex-dividend date of this dividend was Friday, September 25th. This represents a $2.88 annualized dividend and a dividend yield of 3.0%. Medtronic’s dividend payout ratio (DPR) is currently 70.94%.

Insider Buying and Selling at Medtronic

In other news, CEO Geoffrey Martha sold 50,000 shares of the company’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $95.00, for a total transaction of $4,750,000.00. Following the completion of the transaction, the chief executive officer directly owned 277,866 shares of the company’s stock, valued at $26,397,270. This represents a 15.25% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Harry Kiil sold 1,483 shares of the stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total value of $138,882.95. Following the transaction, the executive vice president owned 42,186 shares of the company’s stock, valued at approximately $3,950,718.90. The trade was a 3.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 61,903 shares of company stock valued at $5,889,203 in the last 90 days. 0.27% of the stock is currently owned by company insiders.

Medtronic Profile

Medtronic plc (NYSE: MDT) is a global medical technology company that develops, manufactures and distributes devices and therapies used to diagnose, treat and manage a broad range of medical conditions. Its products support healthcare providers in areas including cardiac and vascular care, diabetes, neuroscience, surgical procedures and patient monitoring.

The company’s offerings include pacemakers, implantable defibrillators, heart valves and other structural heart products; insulin pumps and continuous glucose monitoring technologies; spinal and neurosurgical systems; deep-brain and spinal cord stimulation devices; surgical instruments and robotic-assisted technologies; and respiratory and patient-monitoring equipment.